Fundraising Fox
Axcend
Salt Lake City, US · Founded 2016 · Delaware LLC · 1 known investors
Find your way into Axcend
Sign up to see every warm intro you have to Axcend
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axcend team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Axcend builds compact, portable HPLC (high-performance liquid chromatography) instruments, including the Focus LC line with automated sampling, real-time reaction monitoring, and multi-wavelength UV detection. Its analytical chemistry systems serve pharmaceutical, chemical, and educational customers for lab and production-line analysis.
Founders & leadership
Axcend was founded in 2016 by MILTON L LEE.
ML
MILTON L LEEMANAGER
GD
GLEN D MELLACo-Founder, and CEO2018–2023Glen D Mella served as Chief Marketing Officer and later President & Chief Operating Officer at Control4, where he helped grow the company to over $75 million in revenue and establish operations in more than 75 countries. He previously held leadership roles at Frito-Lay/PepsiCo, WordPerfect, and Novell, and co-founded and served as CEO of Axcend, commercializing liquid chromatography technology developed at Brigham Young University.
Board
BD
BRANDON D FUGALMANAGER
CM
CHRISTOPHER M LEEMANAGER
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.2M disclosed across 6 of 7 rounds · 2018–2023
▶$660.8KraisedFeb 2023 · 6 investors · Other TechnologyRule 506(b)
▶$660.8KraisedFeb 2023 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher M LeeDirector
- Milton L LeeDirector
- Brandon D FugalDirector
- Brent R KnudsenDirector
- Glen D MellaExecutive Officer
- Curtis B HillDirector
- Offering amount
- $2M
- Amount sold
- $660.8K
- Minimum investment
- $17.4K
- First sale
- Feb 2023
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$750KraisedMar 2021 · 2 investors · Other TechnologyRule 506(b)
▶$750KraisedMar 2021 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis B. HillDirector
- Glen D. MellaExecutive Officer, Director
- Brandon D. FugalDirector
- Christopher M. LeeDirector
- Brent R. KnudsenDirector
- Milton L. LeeDirector
- Offering amount
- $1.4M
- Amount sold
- $750K
- Minimum investment
- $250K
- First sale
- Feb 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedMar 2020 · 2 investors · Other TechnologyRule 506(b)
▶$1.7MraisedMar 2020 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brandon D FugalDirector
- Christopher M LeeDirector
- Milton L LeeDirector
- Glen D MellaExecutive Officer, Director
- Brent R KnudsenDirector
- Curtis B HillDirector
- Offering amount
- $2M
- Amount sold
- $1.7M
- Minimum investment
- $700K
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$2.5MraisedMay 2019 · 4 investors · Other TechnologyRule 506(b)
▶$2.5MraisedMay 2019 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brandon D FugalDirector
- Brent R KnudsenDirector
- Curtis B HillDirector
- Glen D MellaExecutive Officer
- Christopher M LeeDirector
- Milton L LeeDirector
- Offering amount
- $3M
- Amount sold
- $2.5M
- Minimum investment
- $67.4K
- First sale
- May 2019
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b, 4a5
▶$500KraisedDec 2018 · 3 investors · Other TechnologyRule 506(b)
▶$500KraisedDec 2018 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- CURTIS B. HILLDirector
- BRANDON D FUGALDirector
- CHRISTOPHER M LEEDirector
- GLEN D MELLAExecutive Officer, Director
- MILTON L LEEDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $100K
- First sale
- Dec 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$1MraisedJun 2018 · 3 investors · Other TechnologyRule 506(b)
▶$1MraisedJun 2018 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- BRANDON D FUGALDirector
- MILTON L LEEDirector
- GLEN D MELLAExecutive Officer
- CHRISTOPHER M LEEDirector
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $150K
- First sale
- Jun 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$400KofferedFeb 2018 · 1 investors · Other TechnologyRule 506(b)
▶$400KofferedFeb 2018 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- BRANDON D FUGALDirector
- CHRISTOPHER M LEEDirector
- MILTON L LEEDirector
- GLEN D MELLAExecutive Officer
- Offering amount
- $400K
- Minimum investment
- $400K
- First sale
- Jan 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
AgilentAgilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors. The company operates through three segments: Life Sciences and Diagnostics Markets (which includes contract manufacturing services for oligonucleotide therapeutics and pathology solutions), Agilent CrossLab (providing lab services and automation), and Applied Markets (offering analytical instruments and software).
AdarepharmasolutionsAdare Pharma Solutions is a CDMO (contract development and manufacturing organization) and pharma services provider serving the biopharma industry with manufacturing, research and development, and patient support capabilities.
PatheonPatheon, part of Thermo Fisher Scientific, is a contract development and manufacturing organization (CDMO) that also offers clinical research (CRO) services for biotechnology and pharmaceutical sponsors. It supports drug development from early-stage R&D through clinical supply and commercial manufacturing across a global network of more than 60 sites.
Companies working in the same space as Axcend.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $258.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $291.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $135K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Axcend do?
- Axcend builds compact, portable HPLC (high-performance liquid chromatography) instruments, including the Focus LC line with automated sampling, real-time reaction monitoring, and multi-wavelength UV detection. Its analytical chemistry systems serve pharmaceutical, chemical, and educational customers for lab and production-line analysis.
- Who founded Axcend?
- Axcend was founded by MILTON L LEE in 2016.
- Who are Axcend's investors?
- Axcend's investors include Partnership Capital Growth LLC.
- How much funding has Axcend raised?
- Axcend has disclosed $7.2M raised across 6 of its 7 known rounds.
- Where is Axcend headquartered?
- Axcend is headquartered in Salt Lake City, US.